148 related articles for article (PubMed ID: 11081461)
1. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
Bergamo A; Zorzet S; Gava B; Sorc A; Alessio E; Iengo E; Sava G
Anticancer Drugs; 2000 Sep; 11(8):665-72. PubMed ID: 11081461
[TBL] [Abstract][Full Text] [Related]
2. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
[TBL] [Abstract][Full Text] [Related]
3. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G
Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274
[TBL] [Abstract][Full Text] [Related]
4. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
5. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
7. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.
Capozzi I; Clerici K; Cocchietto M; Salerno G; Bergamo A; Sava G
Chem Biol Interact; 1998 May; 113(1):51-64. PubMed ID: 9630847
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
9. CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.
Bergamo A; Delfino R; Casarsa C; Sava G
Anticancer Agents Med Chem; 2012 Oct; 12(8):949-58. PubMed ID: 22263785
[TBL] [Abstract][Full Text] [Related]
10. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
Sava G; Frausin F; Cocchietto M; Vita F; Podda E; Spessotto P; Furlani A; Scarcia V; Zabucchi G
Eur J Cancer; 2004 Jun; 40(9):1383-96. PubMed ID: 15177498
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
12. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
[TBL] [Abstract][Full Text] [Related]
13. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
Sava G; Bergamo A; Zorzet S; Gava B; Casarsa C; Cocchietto M; Furlani A; Scarcia V; Serli B; Iengo E; Alessio E; Mestroni G
Eur J Cancer; 2002 Feb; 38(3):427-35. PubMed ID: 11818210
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G
Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
Bicek A; Turel I; Kanduser M; Miklavcic D
Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium antimetastatic agents.
Alessio E; Mestroni G; Bergamo A; Sava G
Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
[TBL] [Abstract][Full Text] [Related]
18. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.
Hostetter AA; Miranda ML; DeRose VJ; McFarlane Holman KL
J Biol Inorg Chem; 2011 Dec; 16(8):1177-85. PubMed ID: 21739255
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
